By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later ...

Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

President Donald Trump's new European tariffs could significantly increase the cost of Novo Nordisk's weight loss drug, Ozempic.

European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as investors ...